Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 8/20 | 0.32 |
| ▸ | METAP1 | P53582 | 6/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18735377 | 0.91 | MGAM (0.38) | METAP2METAP1L3MBTL1POLBKMT2A | |
| SCHEMBL18735351 | 0.90 | METAP2 (0.31) | METAP2METAP1L3MBTL1 | |
| SCHEMBL18735331 | 0.90 | METAP2 (0.33) | METAP2METAP1L3MBTL1POLBKMT2A | |
| SCHEMBL18735373 | 0.87 | L3MBTL1 (0.34) | L3MBTL1ACACBPOLBKMT2A | |
| SCHEMBL18735075 | 0.87 | LMNA (0.33) | METAP2METAP1L3MBTL1POLBKMT2A | |
| SCHEMBL18734971 | 0.82 | — | — | |
| SCHEMBL18735324 | 0.80 | METAP2 (0.32) | METAP2METAP1ACACB | |
| SCHEMBL18735378 | 0.80 | METAP2 (0.32) | METAP2METAP1L3MBTL1POLBKMT2A | |
| SCHEMBL18735337 | 0.80 | CYP1A2 (0.36) | METAP2METAP1L3MBTL1POLBKMT2A | |
| SCHEMBL18734958 | 0.78 | MGAM (0.33) | METAP2METAP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017060400-A1 | PROTECTED CARBOXYLIC ACID-BASED METABOLITES FOR THE TREATMENT OF DISESASES RELATED TO MITOCHONDRIAL DYSFUNCTIONS | NEUROVIVE PHARMACEUTICAL AB (SE) | 2017-04-13 | — | — | WO | disclosed |